Testing a cancer drug to reduce antibodies in multiple sclerosis

This trial is testing whether ixazomib, a medication already used to treat a type of blood cancer called multiple myeloma, might help people with multiple sclerosis. The study focuses on reducing harmful antibodies (called oligoclonal bands) that are found in the fluid surrounding the brain and spinal cord in people with MS. Researchers want to see if this medication can safely reduce these antibodies and potentially slow MS progression.

Multiple sclerosis happens when the immune system attacks the protective coverings of the brain and spinal cord, and a key part of this attack involves special immune cells that make antibodies. Scientists have noticed that these problem cells live in the membranes protecting the brain and spinal cord, so using a medication that can target and eliminate these cells—as ixazomib does in cancer treatment—might offer a new way to help people with MS.